Premium
Syngene International, a subsidiary of Biocon Ltd, a generics major that also owns the country's largest drug research and development services unit, is looking to raise over $50 million, at least two sources privy to the matter told VCCircle. "This is more like a pre-IPO round," said one of the ......
This is a Premium article. Please subscribe or log in to read the full story!
Here's a selection of our recent premium content.
Already a member? Click here to log in.